CanSinoBIO Receives Another Strong Boost

TEDA-based CanSino Biologics Inc. (CanSinoBIO) has received an additional financial boost, securing a grant exceeding US$17 million from Bill & Melinda Gates Foundation, announced by the company on 9th October. This new round of funding is to propel its recombinant poliovirus vaccine (“VLP-Polio”) project forward and will also support potential related combined vaccine candidates. This marks the second funding the innovative VLP-Polio vaccine has received from the Foundation, following the initial grant in October 2023. The VLP-Polio vaccine stands as a non-infectious alternative which promises excellent safety with superior immunogenicity, holding significant potential for global polio control and eradication efforts.

Founded in TEDA in 2009, CanSino Biologics Inc. is dedicated to providing global solutions for the prevention and treatment of infectious diseases. CanSinoBIO has developed five key platform technologies, including viral vector technology, synthetic biotechnology, protein structure design and VLP assembly, mRNA technology as well as formulation and drug delivery technology. The company has built a rich pipeline of 17 innovative vaccine products preventing more than ten diseases.